Peer-reviewed articles


The International Human Papillomavirus Reference Center: Standardization, collaboration, and quality assurance in HPV research and diagnostics. Arroyo Mühr LS, Lagheden C, Hassan SS, et al.

First International Proficiency Study on Human Papillomavirus Testing. Yilmaz E, Eklund C, Lagheden C.

Biosimilar second-generation human papillomavirus vaccines. Arroyo Mühr LS, Dillner J.

Quality assurance in human papillomavirus testing for primary cervical screening. Cuschieri K, Dolores Fellner M, Arroyo Mühr LS, et al.


. Mapping HPV 16 Sub-Lineages in Anal Cancer and Implications for Disease Outcomes. Guerendain D, Arroyo Mühr LS,  Grigorescu R, et al.

Metatranscriptome analysis in human papillomavirus negative cervical cancers. Ure A, Mukhedkar D, Arroyo Mühr LS.

Using HPV-meta for human papillomavirus RNA quality detection. Ure A, Mukhedkar D, Arroyo Mühr LS.

Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study. Arroyo Mühr LS, Eklund C, Lagheden C, et al.

Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses. Arroyo Mühr LS, Eklund C, Lagheden C, et al.

Human Papillomavirus Infection Determines Prognosis in Cervical Cancer. Lei J, Arroyo Mühr LS, Lagheden C, et al.


Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program. Hortlund M, Arroyo Mühr LS, Lagheden C, et al.

Human Papillomavirus Load and Genotype Analysis Improves the Prediction of Invasive Cervical Cancer. Hortlund M., van Mol T, Van de Pol F, et al.

Validation of the cobas 6800 human papillomavirus test in primary cervical screening. Sundström K, Lamin H, Dillner J.

The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing. Eklund C, Arroyo Mühr LS, Lagheden C, et al.

Misclassifications in human papillomavirus databases. Arroyo Mühr LS, Eklund C, Dillner J.

Human Papillomavirus Detection by Whole-Genome Next-Generation Sequencing: Importance of Validation and Quality Assurance Procedures. Arroyo Mühr LS, Guerendiain D, Cuschieri K, et al.

Elimination of HPV–associated oropharyngeal cancers in Nordic countries. Lehtinen T, Elfström KM, Mäkitie A, et al.

Transcription of human papillomaviruses in nonmelanoma skin cancers of the immunosuppressed. Arroyo Mühr LS, Hultin E, Dillner J.


Cervical screening in high-income countries: the need for quality assurance, adjunct biomarkers and rational adaptation to HPV vaccination. Sundström K, Herweijer E, Wang J.

Using machine learning for predicting cervical cancer from Swedish electronic health records by mining hierarchical representations. Weegar R, Sundström K.

More evidence suggesting that 1-dose human papillomavirus vaccination may be effective. Brotherton JML, Sundström K.

Advances in cervical cancer prevention: Efficacy, effectiveness, elimination? Sundström K, Elfström KM.

How many Human Papillomavirus types do we need to screen for? Sundström K, Dillner J.

De novo sequence assembly requires bioinformatic checking of chimeric sequences. Arroyo LS, Lagheden C, Hassan SS, et al.

Increase of Cervical Cancer Incidence in Sweden in Relation to Screening History: Population Cohort Study. Wang J, Andrae B, Strander, B, et al.

Transcription of human papillomavirus oncogenes in head and neck squamous cell carcinomas. Bzhalava Z, Arroyo LS, Dillner J.


Sequencing detects human papillomavirus in some apparently HPV-negative invasive cervical cancers. Arroyo LS, Lagheden C, Eklund C, et al.

HPV transcription in skin tumors. Hultin E, Arroyo LS, Lagheden C, et al.

The HPV16 genome is stable in women who progress to in situ or invasive cervical cancer: a prospective population-based study. Arroyo LS, Lagheden C, Hultin E, et al.

The Launch of an International Animal Papillomavirus Reference Center.Van Doorslaer K, Dillner J.


Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study. Arroyo LS, Lagheden C, Hultin E, et al.

Long-Term Antibody Response to Human Papillomavirus Vaccines: up to 12 Years Follow-Up in the Finnish Maternity CohortArtemchuk A, Eriksson T, Poljak M, et al.

ICTV Virus Taxonomy Profile: Papillomaviridae. Van Doorslaer K, Chen Z, Bernard HU, et al.

Towards quality and order in human papillomavirus research. Arroyo LS, Eklund C, Dillner J.

Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. Lagheden C, Eklund C, Lamin H, et al.

Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV Labnet international proficiency studies. Eklund C, Forslund O, Walling KL, et al.

Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Pinto LA, Dillner J, Beddows S, et al.


Viruses in cancers among the immunosuppressed. Arroyo LS, Bzhalava Z, Hortlund M, et al.

Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. Triglav T, Artemchuk H, Ostrbenk A, et al.

Viruses in case series of tumors: Consistent presence in different cancers in the same subject. Arroyo LS, Hortlund M, Bzhalava Z, et al.

Cancer risks after solid organ transplantation and after long-term dialysis. Hortlund M, Arroyo LS, Storm H, et al.


Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. Lagheden C, Eklund C, Kleppe SN, et al.

Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case-Control Study. Faust H, Andersson K, Luostarinen T, et al.

Sourcing of the WHO human papillomavirus type 18 international standards for HPV antibody levels. Faust H, Eklund C, Ukvirach S, et al.


Does human papillomavirus-negative condylomata exist? Arroyo LS, Bzhalava D, Lagheden C, et al.

International standardization and classification of human papillomavirus types. Bzhalava D, Eklund C, Dillner J.

Long-term HPV type-specific risks for ASCUS and LSIL: A 14-year follow-up of a randomized primary HPV screening trial.  Elfström KM, Smelov V, Johansson AL, et al.

Human papillomavirus type 197 is commonly present in skin tumors. Arroyo LS, Hultin E, Bzhalava D, et al.


Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. Eklund C, Forslund O, Wallin KL, et al.

Deep sequencing extends the diversity of human papillomaviruses in human skin. Bzhalava D, Arroyo LS, Lagheden C, et al.


A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Bzhalava D, Guan P, Franceschi S, et al.

Diversity of human papillomaviruses in skin lesions. Ekström J, Mühr LS, Bzhalava D, et al.

Unbiased approach for virus detection in skin lesions. Bzhalava D, Johansson H, Ekström J, et al.

Metagenomic sequencing of “HPV-negative” condylomas detects novel putative HPV types. Johansson H, Bzhalava D, Ekström J, et al.

Next generation sequencing for human papillomavirus genotyping. Arroyo LS, Smelov V, Bzhalava D, Eklund C, Hultin E, Dillner J.


International collaborative proficiency study of Human Papillomavirus type 16 serology. Eklund C, Unger ER, Nardelli-Haefliger D, et al.